Co-Diagnostics, Inc. CODX
Set alert
0.37 USD -0.03 -7.16%
At close · Oct 30
0.37 0.00 +0.25%
After hours · Oct 30, 7:38 PM ET
0.3649 Day range 0.4001
0.3667 52-week range 14.04
- YTD
- -92.77%
- 1 year
- -97.39%
- Open
- 0.40
- Prev close
- 0.395
- Mkt cap
- 3.24M
- Vol
- 236.05K
- Avg vol
- 361.52K
- EPS
- -26.14
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3649
- High
- 0.4001
- Forward P/E
- -0.62
- Beta
- -0.85
- Short ratio
- 1.77
- Inst. own
- 13.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.06
- 200-d avg
- 1.19
- 1y target
- 1.50
3M chart
Signals (13)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 15, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 6, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 16, 2026 | 1 month ago |
| RSI: Oversold | Sep 8, 2026 | 1 month ago |
| RSI: Oversold | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| RSI: Oversold | Aug 6, 2026 | 2 months ago |
Key statistics
- Market cap
- 23.28M
- Enterprise value
- -11.98M
- Trailing P/E
- 0.00
- Forward P/E
- -0.62
- PEG ratio
- 0.00
- Price / sales
- 3.18
- Price / book
- 0.36
- EPS (TTM)
- -1.38
- Beta
- -0.85
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.32M
- Revenue growth
- -73.90%
- Free cash flow
- -12.79M
- Total cash
- 37.66M
- Total debt
- 2.37M
- Return on equity
- -50.57%
- Shares outstanding
- 31.93M
- Short % of float
- 0.76%
- 50-day average
- 1.06
- 200-day average
- 1.19
Analyst view
Consensus: none
Price target (mean) 1.50
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.34.
Financials — quick view
CODX Revenue — quarterly 166.13K
CODX Net income — quarterly -6.28M
CODX EPS — quarterly -1.46
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.33 | -0.32 | +0.01 | +3.03% |
| Aug 8, 2024 | Jun 1, 2024 | -0.34 | -0.25 | +0.09 | +26.47% |
| Aug 8, 2024 | Jun 1, 2024 | -0.34 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.21 | -0.31 | -0.10 | -47.62% |
| May 9, 2024 | Mar 1, 2024 | -0.21 | — | — | — |
| Mar 14, 2024 | Dec 1, 2023 | 0.00 | -0.50 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 12, 2024 | HC Wainwright & Co. | main | Neutral | Neutral |
| Jun 17, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| May 13, 2024 | HC Wainwright & Co. | main | Neutral | Neutral |
| Mar 15, 2024 | HC Wainwright & Co. | main | Neutral | Neutral |
| Dec 29, 2023 | HC Wainwright & Co. | reit | Neutral | Neutral |
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- codiagnostics.com
News
- Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast
- Co-Diagnostics Announces Publication Of Peer-Reviewed Study Using SARAGENE Human Papillomavirus High Risk Test Manufactured By CoSara Diagnostics
- Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test
- Co-Diagnostics Moves Closer to Commercial Tuberculosis Test Launch in India
- Co-Diagnostics's India JV CoSara Diagnostics Completes Its Clinical Performance Study Of The CoSara PCR Mycobacterium Tuberculosis Test On CoSara PCR Pro Instrument; Has Submitted Test To India's Central Drugs Standard Control Organization For Regulatory Clearance
- Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India
- Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
- Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
- Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
Your note
Sign in to keep a note on CODX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABBOTT RICHARD DAVID | President | Stock Award(Grant) | Nov 21, 2024 | 13,915 |
| BROWN BRIAN LEE | Chief Financial Officer | Stock Award(Grant) | Nov 21, 2024 | 419,905 |
| DURENARD EUGENE A | Director | Conversion of Exercise of derivative security | Nov 21, 2024 | 163,333 |
| EGAN DWIGHT H. | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 21, 2024 | 522,858 |
| MURPHY TED | Director | Conversion of Exercise of derivative security | Nov 21, 2024 | 175,833 |
| NELSON JAMES B | Director | Conversion of Exercise of derivative security | Nov 21, 2024 | 163,333 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 5.58% | 1,781,283 | 1.30M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.78% | 567,722 | 413.93K | Sep 29, 2024 |
| Blackrock Inc. | 1.58% | 504,382 | 367.74K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.01% | 321,275 | 234.24K | Sep 29, 2024 |
| Bridgeway Capital Management, Inc. | 0.85% | 272,900 | 198.97K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.59% | 187,569 | 136.76K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4.01% | 1,279,125 | 932.61K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.39% | 444,776 | 324.29K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.85% | 272,900 | 198.97K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.54% | 172,056 | 125.45K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.22% | 69,770 | 50.87K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.17% | 53,201 | 38.79K | Oct 30, 2024 |